Tags : Lung Imaging

Polarean Reports the NDA Submission of Hyperpolarised 129Xenon Gas Drug-Device

Tuba Khan October 8, 2020

Shots: The company reports NDA submission and request for PR to the US FDA for hyperpolarised 129Xenon gas used to evaluate the pulmonary function and to visualize the lung using […]readmore

Regulatory

Curium’s Pulmotech MAA Receives the US FDA’s Approval for Lung

Vartika Singh March 24, 2020

Shots: Pulmotech MAA is a single-photon emission agent targeted for lung imaging as an adjunct in the evaluation of pulmonary perfusion, further aiding the evaluation of peritoneovenous shunt patency in […]readmore

Tags : Lung Imaging

Polarean Reports the NDA Submission of Hyperpolarised 129Xenon Gas Drug-Device

Curium’s Pulmotech MAA Receives the US FDA’s Approval for Lung

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Lung Imaging

Polarean Reports the NDA Submission of Hyperpolarised 129Xenon Gas Drug-Device

Curium’s Pulmotech MAA Receives the US FDA’s Approval for Lung

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company